Westlake Village, Calif. (PRWEB) January 15, 2014
Cynvenio, a cancer diagnostics company focused on transforming cancer treatment and management through the genomic analysis of tumor cells in the bloodstream, today announced that it will offer Therapy Finder™, a web-based cancer decision support application powered by CollabRx, Inc.
Available as a reporting option with Cynvenio’s ClearID™ genomic test, Therapy Finder will provide breast cancer patients and their physicians with a dynamic resource to navigate and understand both the current standard of care as well as cutting edge experimental therapy options with the goal of enabling patients to receive the best possible care. ClearID customers will gain access to focused news and patient-oriented educational material on advances in breast cancer, the latest medical and scientific research, risk factors for recurrence, monitoring, and early detection. The breast cancer Therapy Finder is dynamically updated and curated by CollabRx medical and scientific personnel with the support of an editorial board composed of independent breast cancer clinical experts. The Therapy Finder for Breast Cancer is the most recent electronic decision support application released by CollabRx and complements existing Therapy Finders for lung cancer, colorectal cancer, and melanoma. It is the first such app developed specifically for a patient user.
ClearID is Cynvenio’s monitoring test for breast cancer survivors at high risk of disease recurrence. It analyzes DNA from tumor cells in the bloodstream for cancer-associated genomic mutations which can be used to characterize disease status and available treatment options. Through the partnership with CollabRx, clinicians and researchers ordering ClearID tests from Cynvenio will also have the option of requesting genomic reporting via the Genetic Variant Annotation (GVA) ServiceTM which provides clinically actionable and dynamically upda
Copyright©2012 Vocus, Inc.
All rights reserved